Revenue Rises, Profit Falls — The Real Story Behind the Expansion
Q2 delivered 12.5% revenue growth but a 28.2% profit decline. The margin compression is real, management quietly cut full-year guidance, and the bull case now depends entirely on Phase-3 execution and export mix tilt.
₹192.6 Cr
+12.5% YoY, +43% QoQ
₹33.0 Cr
−28.2% YoY, +58% QoQ
20.8%
vs 16.4% Q1, vs 28–29% historical
₹750 Cr
revised down from ₹800 Cr
The Gap That Defines the Quarter
On paper, Q2 looks strong: revenue up 12.5%, order book healthy at ₹550+ Cr, Phase-3 expansion on track. But the one number that matters — profit — fell 28.2% year-on-year. That disconnect is not a typo; it is the quarter. Revenue came in, but margin didn't follow. Freight and raw material costs, elevated from Middle East crisis fallout and global supply tightness, ate away at the bottom line. EBITDA margin of 20.8% sits 7–8 percentage points below historical 28–29% levels. Management's answer: transient. The market's answer: a 34% drawdown from the all-time high of ₹5,399.
What Management Claimed vs. What Holds Up
FY27 revenue guidance of ₹800 Cr on track
ContradictedMD now targeting ₹750 Cr. Prior ₹800 Cr guidance withdrawn but never formally restated on call.
EBITDA margin improving Q1 to Q2
SupportedQ1 16.4%, Q2 20.8% — confirmed in the numbers. +440 bps QoQ is real.
Export mix 40% domestic, 60% export
OverstatedMD said 'anywhere between probably 40% to 60%' when pressed. Non-committal band, not a clear split.
Raw material costs stabilizing; margin recovery likely
OverstatedRM at 71–72% of sales (vs 60% prior). MD admits 'not sure costs will fall.' Pricing pass-through to customers 'now starting.'
Order book ₹550+ Cr covers 6+ months
SupportedH1 revenue ~₹330 Cr; H2 needs ~₹420 Cr to hit ₹750 Cr full-year. Order book supports execution but margin is tight.
What Changed on This Call
FY27 revenue guidance cut from ₹800 Cr to ₹750 Cr (~6.25% reduction, not formally restated)
EBITDA margin recovery timeline pushed to Q3+ (not achieved in Q2 as prior optimism suggested)
Export momentum confirmed recovering post-US tariff removal (Feb 2026); North America lead-times 1–1.5 years
Phase-3 (6,500 MVA, 220 kV class) commissioning April 2027 remains on track; total capacity 14k MVA
FY28 target ₹1,000 Cr, FY29 ₹1,250–1,500 Cr reiterated; contingent on Phase-3 ramp and export mix hold
Reconciling the Margin Story
In H1, raw material costs rose from 60% to 71–72% of sales. Freight, still elevated from Middle East supply disruptions, added further drag. Q2 EBITDA of ₹40.06 Cr represents a 20.8% margin — better than Q1's 16.4%, but a structural 7–8 pp gap versus 28–29% historical levels. Management's thesis: three levers close the gap. First, export revenue tilt. Exports command materially higher EBITDA margins than domestic (exact % undisclosed), and post-tariff momentum in North America is real. Second, capacity utilization moving from 80–90% to 100% by Q3, driving scale economies. Third, raw material cost pass-through on new orders now 'starting.' But none of these are guaranteed. Export demand could stall, new capacity could cannibalize margins industry-wide (Wauree and peers are all expanding), and pricing power may not hold if demand softens.
The RM prices have stabilized. Again, it is not as what it used to be. And I don't think that it will completely stabilize till all the Middle East crisis and other things gets concluded.
The Bull-Bear Ledger
Phase-3 expansion (April 2027) adds 6,500 MVA and unlocks 220 kV approvals in 3–6 months post-live
Order book ₹550+ Cr validates demand; FY28 ₹1,000 Cr target is quantified not speculative
Export recovery post-US tariff withdrawal is concrete (lead-time 1–1.5 years, pent-up demand)
PAT fell 28.2% YoY despite revenue growth — margin compression is structural, not transient
FY27 guidance quietly cut 6.25% (₹800 Cr → ₹750 Cr); margin targets (28–29%) not in sight
Industry-wide capacity glut (Wauree, others expanding) threatens pricing power near-term
Working capital up to ₹200 Cr in H1; cash drag during Phase-3 capex if sales ramp stalls
Management tone confident but vague on margin specifics; evasive when pressed on export % and RM cost headwinds
Risks, Ranked by How Much They Should Concern a Holder
Margin recovery doesn't materialize (stuck at 20–22% vs 28–29% historical)
HighPAT decline despite revenue growth suggests structural headwind, not transient. If freight/RM normalisation takes years or doesn't happen, FY27–28 earnings growth stalls. Street already priced in margin compression; further disappointment triggers repricing.
Guidance credibility. FY27 cut from ₹800 Cr to ₹750 Cr without formal restatement
HighAnalysts had to infer downgrade. If H2 misses ₹420 Cr revenue (needs to hit ₹750 Cr), another cut likely. Damages forward guidance confidence for FY28 ₹1,000 Cr target.
Phase-3 execution delay or 220 kV approval >6 months post-live
MediumApril 2027 commissioning is tight. If delayed, FY28 ramp to ₹1,000 Cr at risk. 220 kV class is key differentiation; delay erodes margin restoration thesis.
Export market volatility (Middle East, Europe geopolitical) or North American demand softening post-tariff recovery
MediumBull case relies on 50–60% export mix and higher export EBITDA margins. If export orders disappoint, company reverts to higher-mix domestic (lower margin) to absorb capacity.
Industry oversupply pressures pricing further
MediumWauree, others adding capacity. If transformer pricing deteriorates below RM cost inflation, margin floor erodes. Management's 'higher-MVA premium' may not hold.
Working capital cycle elongates during Phase-3 capex ramp
LowWC already ₹200 Cr in H1. If sales ramp without cash conversion acceleration, liquidity stress. Mitigated by interest-bearing LC structure, but cash drag remains.
How the Street Is Positioned
The stock sits at ₹3,565.8, down 34% from its all-time high of ₹5,399 and trading below its 20-, 50-, and 200-day moving averages (₹3,810, ₹3,951, and ₹4,083 respectively). RSI at 38.2 signals neutral momentum — not oversold, but heavy. Volume is normal, not panic. The sharp drawdown aligns perfectly with the fundamental story: the market priced in expansion upside; Q2 delivered margin compression and a guidance cut instead. Ownership remains stable — FII at 2.57%, DII at 1.95%, promoter at 62.12% — no distress selling. The bearish price action is not a warning of hidden problems; it is the market rationally repricing the earnings outlook. The bull case (Phase-3 + export recovery → ₹1,000 Cr FY28 + margin restoration) is still intact, but the path is narrower and riskier than prior consensus assumed.
The Debate
What to Watch Next
1 · H2 FY27 revenue delivery
H1 delivered ~₹330 Cr. H2 needs ₹420 Cr to hit revised ₹750 Cr full-year target. Order book ₹550+ Cr supports execution, but this is the first real test of guidance rigor. Miss here, and another downgrade is likely.
2 · Q3 FY27 EBITDA margin
Management targeted 100% capacity utilization and margin inflection by Q3. If Q3 EBITDA margin doesn't reach 23–24%+, cost pass-through is stalling and FY28 margin recovery story breaks.
3 · Phase-3 April 2027 commissioning and 220 kV approval timeline
April live date must hold; any 4-week slip delays 220 kV approvals into Q3-Q4 FY28, deferring revenue ramp. Approvals within 3–6 months post-live are critical for FY28 ₹1,000 Cr credibility.
Shilchar is not broken, but it's not the growth story the market was trading last year. Revenue is real, order book is real, expansion is real. But the margin compression from freight and raw material cost inflation exposed a near-term vulnerability the prior call glossed over. The 34% drawdown from ATH is not irrational; it reflects a repricing of the earnings path, not a repricing of the business fundamentals.
Hold if you own it and believe Phase-3 + exports close the margin gap by FY28-end. The stock could re-rate to ₹4,500–5,000 if execution is clean. But the bar for credibility is high now — every quarter counts. The number to track from here is EBITDA margin, quarter on quarter. If Q3–Q4 FY27 margins stay in the 20–22% range, the long-term thesis is at risk. If they inflect to 24%+, the bull case validates and the stock rallies. The debate will be won or lost in the next two earnings prints.
Informational and educational content only. Not investment advice.